Metastatic Breast Cancer

Channeling the fear of unwanted change into the hard-fought promise of a transformed life.

In order to combat resistance to certain treatments for patients with metastatic breast cancer, researchers look to a novel combination of pyrotinib plus Xeloda to help increase progression-free survival in patients.

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy improves progression-free survival in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.

Traveling with cancer during a pandemic requires some planning. Here's how I did it safely.

Mary Trouba, a patient with metastatic inflammatory breast cancer, talks about the 20 things she has learned on her own cancer journey.

Metastatic breast cancer doesn’t keep Nalie Agustin from raising awareness and empowering others.

“This is the first randomized trial to demonstrate an overall survival benefit for patients with brain metastases, which I think is very significant,” said Dr. Nancy U. Lin.

We are proud of our ANGEL Advocates who are leading through example as we mobilize nationally and globally to #StayHome. Read their blogs to learn more about what they’ve been doing during these uncertain times.

One person with cancer details their challenges with fighting for social security while battling a metastatic breast cancer diagnosis.

It's not just time spent sitting in the lobby. Waiting is a way of life for people with cancer.

Cancer changes us, and often we find new parts of ourselves that help us accomplish new goals in the face of adversity and tragedy.

The Food and Drug Administration’s recent approval of the first antibody-drug conjugate to treat patients with pretreated metastatic triple-negative breast cancer is a major milestone, according to one expert.

The Food and Drug Administration approved the targeted therapy Tukysa as part of a drug combination to treat HER2-positive breast cancer. Here’s what you need to know.

Looking at new data from the phase 3 PEARL trial, Dr. Melissa K. Accordino discusses how the use of CDK4/6 inhibitors could help patients with HR-positive/HER2-negative metastatic breast cancer move away from chemotherapy.

Choosing the best path forward is hard under any circumstance, but today, those decisions are wrought with additional unknowable risks.

Survival strategies for her best life help this metastatic cancer patient navigate a new world in the wake of the COVID-19 pandemic.

The Food and Drug Administration approved an updated dose of Ontruzant, a biosimilar to Herceptin, for multiple cancer types.

Understanding a diagnosis is not just something for a patient's care team, the patient needs to understand their diagnosis as well.

Don’t be worried to get a second opinion — it could save your life.

The COVID-19 pandemic has reached across the globe and continues to change, rapidly impacting everyone. Here are some of the stories around the world highlighting how the pandemic has impacted the lives of patients with cancer.

The combination of Kisqali and Faslodex shows improved overall survival in patients with hormone-receptor-positive, HER2-negative advanced breast cancer.

A recent study looking at data from three clinical trials involving Nerlynx shows promise for the future of treating patients with HER-2 positive breast cancer who develop CNS metastases.

Despite differences in tumors, the addition of CDK 4/6 inhibitors to endocrine therapy showed a benefit in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer compared with endocrine therapy alone.

The three-drug combination of Perjeta and Herceptin with Gemzar shows improved progression-free survival in patients with metastatic breast cancer to advance to a phase 3 trial.

When making treatment decisions in breast cancer, patient concerns about how each treatment will affect their daily life — and their disease stage — have an important role to play, according to Dr. Sara Hurvitz.